Fluoxetine treats six conditions with full FDA approval: major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, bipolar depression, and treatment-resistant depression. It belongs to a class of medications that increase serotonin activity in the brain, and it’s one of the most widely prescribed antidepressants in the world, available under the brand name Prozac among others.
Major Depressive Disorder
Depression is the most common reason fluoxetine is prescribed. It’s approved for both short-term treatment of depressive episodes and long-term maintenance to prevent relapse. In adults, it’s typically the first or second medication tried for moderate to severe depression.
Fluoxetine is also one of the few antidepressants approved for children and adolescents with depression, specifically ages 8 and older. That approval came from two placebo-controlled trials involving 315 pediatric patients that showed meaningful symptom improvement over 8 to 9 weeks.
Obsessive-Compulsive Disorder
Fluoxetine is approved for treating the obsessions and compulsions that define OCD in both adults and children ages 7 and older. People with OCD experience intrusive, unwanted thoughts (obsessions) and feel driven to perform repetitive behaviors (compulsions) to relieve the distress those thoughts cause. Fluoxetine can reduce the intensity and frequency of both.
The pediatric approval for OCD was based on a 13-week trial of 103 patients ages 7 to 17. OCD often requires higher doses than depression, and it can take longer to see full improvement.
Bulimia Nervosa
Fluoxetine is the only antidepressant with specific FDA approval for bulimia nervosa. It’s used to reduce the frequency of binge-eating and purging episodes in people with moderate to severe symptoms. This approval applies to adults only. The effect appears to be somewhat independent of whether the person also has depression, meaning fluoxetine targets the binge-purge cycle on its own rather than just improving mood.
Panic Disorder
Fluoxetine is approved for panic disorder, with or without agoraphobia (the avoidance of places or situations that trigger panic). It reduces the frequency and severity of panic attacks over time. This is an adult-only indication. Because fluoxetine can temporarily increase anxiety during the first week or two of treatment, prescribers often start at a lower dose for people with panic disorder.
Bipolar Depression and Treatment-Resistant Depression
For two more serious conditions, fluoxetine is approved only when combined with olanzapine, an antipsychotic. Together, these medications are used to treat depressive episodes in bipolar I disorder and treatment-resistant depression, which is defined as depression that hasn’t improved after two adequate trials of different antidepressants.
The bipolar depression indication covers adults and children ages 10 and older. This is notable because fluoxetine alone is generally not recommended for bipolar disorder, as it may trigger manic episodes without the mood-stabilizing effect of the second medication.
Premenstrual Dysphoric Disorder
Fluoxetine is also widely used to treat premenstrual dysphoric disorder (PMDD), a severe form of PMS that causes significant mood symptoms like irritability, tension, and dysphoria in the two weeks before menstruation. A version of fluoxetine was previously marketed under the brand name Sarafem specifically for this condition.
One of the advantages for PMDD is dosing flexibility. Some people take fluoxetine every day throughout the month, while others use “luteal phase dosing,” meaning they only take it during the symptomatic premenstrual phase starting around day 14 of their cycle and stopping when menstruation begins. This approach cuts monthly medication exposure by half or more while still providing relief. Clinical trials found that a daily dose of 20 mg was both effective and well tolerated, while higher doses didn’t add meaningful benefit and caused more side effects.
How Fluoxetine Works
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). After nerve cells release serotonin to send a signal, they normally reabsorb it. Fluoxetine blocks that reabsorption, leaving more serotonin available in the gaps between nerve cells. Over time, this increased serotonin activity appears to recalibrate mood regulation, anxiety responses, and compulsive behaviors.
One thing that sets fluoxetine apart from other SSRIs is how long it stays in your system. After you’ve been taking it regularly, the drug itself has a half-life of 4 to 6 days, and your body converts it into an active byproduct that lasts even longer, with a half-life averaging about 9 days. This means fluoxetine lingers in your system for weeks after you stop taking it. That’s a practical advantage: missing a dose or two is less likely to cause the withdrawal-like discontinuation symptoms that are common with shorter-acting antidepressants. It also means the medication builds up gradually and clears slowly, which is worth knowing if you’re switching to a different drug.
How Long It Takes to Work
Fluoxetine doesn’t work overnight, but it works faster than many people expect. A study tracking the onset of response found that among people who ultimately responded to fluoxetine, more than half noticed improvement by week 2. By week 4, roughly 80% of eventual responders had started to feel better.
The flip side of those numbers is equally useful. If you’ve seen no improvement at all by weeks 4 to 6, there’s a 73% to 88% chance the medication won’t work for you at the standard timeline of 8 weeks. That doesn’t necessarily mean giving up on fluoxetine entirely (dose adjustments are common), but it’s a reasonable point to have a conversation with your prescriber about next steps.
Safety Considerations by Age
All antidepressants, including fluoxetine, carry an FDA boxed warning about an increased risk of suicidal thoughts and behavior in younger patients. The numbers from pooled clinical trials break down clearly by age group. Compared to placebo, antidepressants were associated with 14 additional cases of suicidal thinking per 1,000 patients treated in those under 18, and 5 additional cases per 1,000 in adults ages 18 to 24.
The pattern reverses in older adults. In the 25 to 64 age range, there was actually 1 fewer case per 1,000 patients compared to placebo. In adults 65 and older, antidepressants were associated with 6 fewer cases per 1,000. This doesn’t mean fluoxetine is unsafe for young people; it means close monitoring matters, especially in the early weeks of treatment or after dose changes, when mood can shift unpredictably before stabilizing.